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Vemurafenib is active against metastatic melanoma with BRAF V600E mutation.1,2 BRAF mutations were reported 
in 3% to 5% of non–small-cell lung cancers (NSCLC) by the 
US Lung Cancer Mutation Consortium and by Italian investi-
gators.3,4 In vitro, MEK inhibition in lung cancer cell lines with 
V600E induced apoptosis, but clinical experience with drugs 
targeting the RAS/RAF/MEK pathway in  V600E-NSCLC is 
limited.5
CASE REPORT
An 80-year-old man was admitted to our hospital with 
a history of shortness of breath and hoarseness. He was a for-
mer smoker and received torasemide (a diuretic) for hyperten-
sive heart disease. Computed tomography (CT) scan showed a 
central tumor in the left lung, mediastinal lymph node metas-
tases, and left pleural effusion (Fig. 1A). Drainage of pleural 
and pericardial effusion was performed, followed by pericar-
dial instillation of bleomycin and talc slurry of the left pleura. 
Cytology revealed thyroid transcription factor-1 positive can-
cer cells, consistent with the diagnosis of NSCLC stage M1a 
(Fig. 2A). Polymerase chain reaction and direct sequencing 
showed BRAF V600E mutation (Fig. 2B). Sequencing of epi-
dermal growth factor receptor exon 18 to 21, KRAS exon 2, 
and human epidermal growth factor receptor 2 exon 19 to 20 
was negative. Anaplastic lymphoma kinase fluorescence in situ 
hybridization was also negative. The performance status was 4, 
the prognosis was very poor, chemotherapy was not recom-
mended, and the patient was ineligible for a clinical trial with 
an MEK inhibitor. After exclusion of contraindications, the 
patient was offered vemurafenib off-label use. Pretreatment 
fluorodeoxyglucose–positron emission tomography/CT was 
performed (Fig. 1B), vemurafenib was initiated at the regu-
lar dose of 960 mg bid, and the patient left the hospital in a 
stable condition supported by family and professional home 
care. After 1 week of vemurafenib, his clinical and labora-
tory parameters were stable, and he decided to continue. 
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FIGURE 1. A, CT scan at diagnosis with a tumor in the left 
lung (long arrow), mediastinal lymph node metastases (short 
arrow), left pleural effusion (arrowheads), and pericardial 
effusion; (B) pretreatment FDG-PET/CT with increased FDG 
uptake (SUV max. 13.3) in the lung tumor (long arrow) and 
the mediastinal nodes (SUV max. 15.0, short arrow), and 
pleural effusion (arrowheads); and (C ) follow-up FDG-PET/
CT after 2 weeks of vemurafenib with decreased uptake in the 
lung tumor (SUV max. 5.5, long arrow) and in the mediastinal 
nodes (SUV max. 6.2, short arrow). CT, computed tomogra-
phy; FDG, fluorodeoxyglucose; PET, positron emission tomog-
raphy; SUV max., maximum standardized uptake value.
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FIGURE 2. A, Diagnostic cytology with thyroid transcription factor-1–positive cancer cells and (B) Sanger sequencing read with 
heterozygous T-A mutation (arrow) in codon 600 of BRAF. C Autopsy with macroscopic appearance of tumor fibrosis in the left 
lung (arrow) and (D) representative histopathology section with residual tumor cell islet (arrow) surrounded by fibrotic tissue 
(arrowheads), consistent with significant tumor regression after vemurafenib therapy.
After 2 weeks, follow-up fluorodeoxyglucose–positron 
emission tomography/CT showed good metabolic response 
(Fig. 1C). The condition of the patient was stable, and he 
remained on treatment. Three days later, he was admitted to 
the emergency room with worsening of dyspnoe, and clinical 
examination revealed progressive bilateral pleural effusions. 
Vemurafenib was stopped, the patient received terminal care, 
and died. Autopsy showed massive bilateral pleural effusions, 
global heart dilatation, and severe biventricular hypertrophy. 
Cytology showed near complete absence of cancer cells in 
pleural fluid, and histology showed massive tumor regression 
with fibrosis and few residual cancer cell islets (Fig. 2C, D). 
N-terminal B-type natriuretic peptide in archived pretreat-
ment serum was 1880 pg/ml, consistent with chronic cardiac 
failure. To the best of our knowledge, this is the first report 
of a patient with V600E-NSCLC responding to vemurafenib. 
Unfortunately, the patient did not obtain clinical benefit 
because he died from a comorbidity without evidence of drug 
toxicity. We hope that this report may encourage further study 
on vemurafenib in V600E-NSCLC.
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